3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
927
Neoplasms
609
Breast Neoplasms
605
Colorectal Neoplasms
458
Neoplasm Metastasis
394
Ovarian Neoplasms
328
Melanoma
313
Prostatic Neoplasms
311
Lung Neoplasms
294
Multiple Myeloma
292
Recurrence
278
Squamous Cell Carcinoma of Head and Neck
246
Stomach Neoplasms
229
Pancreatic Neoplasms
229
Leukemia, Myeloid, Acute
220
Triple Negative Breast Neoplasms
191
Endometrial Neoplasms
190
Carcinoma, Renal Cell
182
Lymphoma, Non-Hodgkin
179
Carcinoma, Hepatocellular
177
Small Cell Lung Carcinoma
165
Leukemia, Lymphocytic, Chronic, B-Cell
156
Advanced Solid Tumors
156
Lymphoma, Follicular
148
Urinary Bladder Neoplasms
139
Lymphoma, Large B-Cell, Diffuse
138
Lymphoma
137
Advanced Solid Tumor
137
Uterine Cervical Neoplasms
134
Head and Neck Neoplasms
134
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biochemically Recurrent Prostate Cancer
×
1 year
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts